Quick Answer
Design Therapeutics, Inc. reported Total Assets of $226.20 million for the year ending 2025.
- Design Therapeutics, Inc. showed a decrease of -10.3% in Total Assets from 2024 to 2025.
- This data is from Design Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $411.85 million | Q2 2021: $405.15 million | Q3 2021: $400.35 million | Q1 2022: $378.80 million | Q2 2022: $367.93 million | Q3 2022: $354.57 million | Q1 2023: $324.74 million | Q2 2023: $311.63 million | Q3 2023: $299.87 million | Q1 2024: $278.79 million | Q2 2024: $269.58 million | Q3 2024: $261.63 million | Q1 2025: $237.48 million | Q2 2025: $222.89 million | Q3 2025: $211.77 million.
- Over the full 6 years of available data (2020 to 2025), Design Therapeutics, Inc.'s Total Assets has grown by 519.5%.
- Historical annual values: Fiscal year 2025: $226.20 million | Fiscal year 2024: $252.09 million | Fiscal year 2023: $289.64 million | Fiscal year 2022: $341.14 million | Fiscal year 2021: $390.56 million | Fiscal year 2020: $36.52 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: